MedCity News

NOVEMBER 20, 2022

There are currently 97 global digital health companies that are considered unicorns. But getting caught up with the idea of digital health unicorns isn’t very sustainable, according to Emilly Melton, managing partner at Threshold Ventures. Instead of focusing too much on their valuations, she recommended that startups simply focus on getting the capital they need in order to reach the next stage of inflection.

Management 121

Management 121

Pharmaceutical Technology

NOVEMBER 20, 2022

The UK's National Institute for Health and Care Excellence (NICE) has published a draft guidance that does not recommend the use of five major Covid-19 therapies. This news came as many organisations and patient advocacy groups have been campaigning for the adoption of some of the rejected drugs for several months, amidst concerns about access to medicines in the UK.

Government 111

Government Medicine Pharmaceutical Consulting 111

pharmaphorum

NOVEMBER 20, 2022

Elizabeth Holmes, the founder and former chief executive of blood testing biotech Theranos, has been sentenced after being convicted of defrauding investors in the company earlier this year, receiving a prison sentence of more than 11 years in a California court. That’s shorter than the 15 years sought by prosecutors, but considerably longer than the 18 months’ house arrest that Holmes’ defense attorneys had pushed for, and there is likely to be an appeal against the sentence,

FDA 111

FDA Patients Management Marketing 111

MedCity News

NOVEMBER 20, 2022

For far too long, dentists have focused on drilling and billing rather than optimizing the patient experience — and that’s driving many of our patients away, with terrible results for their dental health.

Patients 114

Patients Physicians 114

Advertisement

Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud

Distribution

pharmaphorum

NOVEMBER 20, 2022

The COVID-19 pandemic stopped the world in its tracks. It provided a range of new challenges for industry stakeholders, including governments, public health bodies, and regulatory agencies – to name a few. In addition, it offered the opportunity for new solutions and approaches to many of today’s healthcare challenges. The world responded to the crisis at unprecedented speed, as leaders and experts focused on different ways to operate and succeed within the constraints of a new dynamic.

Recruitment 89

Recruitment Consulting Government Management 89

MedCity News

NOVEMBER 20, 2022

Eli Lilly’s stalled cancer drug prexasertib has another chance under Acrivon Therapeutics, whose IPO will fund a fresh slate of mid-stage clinical trials. While attention is focused on the former Lilly asset, also at stake is Acrivon’s technology platform that relies on proteomics rather than genomics for identifying patients appropriate for targeted therapies.

Patients 105

Patients Biopharma Pharma 105

MedCity News

NOVEMBER 20, 2022

When asked if they had heard about their state returning to Medicaid renewals once the public health emergency ends, 62% said they haven’t heard anything, a new report found. Only 5% said they’ve heard a lot about it.

97

97

pharmaphorum

NOVEMBER 20, 2022

Immatics has become the latest partner for GSK in the area of cell therapy for cancer to see its alliance shelved, just two and a half years after being set up. In its third-quarter results update , the Tuebingen, Germany-based biotech said it had been informed by GSK in early October that it would be terminating their partnership announced in February 2020, adding that the decision was made “unrelated to the programmes and the progress achieved in the collaboration to date.” The de

Leads 57

Leads 57

MedCity News

NOVEMBER 20, 2022

MedCity News interviews CEOs of public companies, entrepreneurs, VCs and payers who had a range of varying answers to the question. But one common theme emerged: everyone, currently, has a vise-like grip on expenditure.

Healthcare 94

Healthcare Healthcare 94

PharmExec

NOVEMBER 20, 2022

Webinar Date/Time: Thu, Dec 8, 2022 2:00 PM EST.

Safety 52

Safety 52

Advertisement

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

Safety